Zymeworks scores $61.5 mln Series A
Vancouver, British Columbia-based Zymeworks, a biotherapeutics company, has raised $61.5 million in Series A funding. BDC Capital and Lumira Capital led the round with participation from other investors that included Eli Lilly and Company, Celgene, CTI Life Sciences Fund, the Fonds de solidarité FTQ. Perceptive Advisors, Teralys Capital, Northleaf Venture Catalyst Fund, Brace Pharma Capital and Merlin Nexus. In addition to the funding, Dion Madsen, a senior managing partner at BDC Capital’s healthcare venture fund, has been added to Zymeworks’ board of directors while Dr. Daniel Hétu, a managing director at Lumira Capital, will become an observer.
8 January 2016•3 mins read
